Ondas Order Surge: Positive for Revenue, Not Enough for Upgrade

What happened

Ondas announced an additional $165 million in new orders, bringing total orders since June 30 to over $270 million, extending revenue visibility into 2027. This builds on an already substantial backlog, but the company's financials remain strained, with Q2 adjusted EBITDA loss of $50.6 million and operating cash outflow of $137.4 million in the first half of 2026. The order growth is real, but much of recent revenue gains have come from acquisitions, and integration of purchases like DZYNE and Cyberhawk is incomplete, while shares outstanding have ballooned to 569.8 million. Management has repeatedly raised guidance, but the stock has not responded as strongly as one might expect, reflecting investor skepticism about whether scale will translate into profitability. Ultimately, these new orders are a positive data point but do not by themselves resolve the core issues of cash burn, dilution, and execution risk.

Implication

The new orders extend the revenue runway into 2027, but the market is likely to reward only delivery, not just bookings. The key near-term catalyst remains Q3 earnings: revenue must land within the $140-155 million guidance and adjusted EBITDA must improve from the Q2 loss of $50.6 million. Share count has grown rapidly, and the January 2027 delivery of 45 million DZYNE shares will further pressure per-share metrics. While defense demand is strong, Ondas faces intense competition from larger players like Anduril, and its assembled capabilities are unproven in terms of margin stability. Therefore, we would hold current positions and consider adding only on a pullback to the attractive entry zone around $6.25 or after clear evidence of operational leverage.

Thesis delta

Thesis remains largely unchanged; the new orders bolster revenue visibility but do not alter the fundamental concerns around profitability, integration, and share count. The rating of WAIT is maintained, but the order flow slightly increases confidence in the revenue trajectory, though it does not warrant an upgrade until we see evidence of EBITDA improvement and reduced dilution.